Logo

Personalis: Karin Eastham

Sep 13, 2019

Menlo Park, California-based Personalis has appointed Karin Eastham as independent director to its board of directors. Eastham currently serves as board member for Geron, Veracyte, and Nektar Therapeutics. Prior to Personalis, Eastham served as executive VP and chief operating officer, as well as a member of the board of trustees, at the Burnham Institute for Medical Research from 2004 to her retirement in 2008. She previously served on the boards of Illumina, MorphoSys, Trius Therapeutics, Amylin Pharmacueticals, Genoptix, Tercica, and SGX Pharmaceuticals. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.